Sorafenib (Nexavar̄, BAY 43-9006)-induced hand-foot skin reaction with facial erythema

Annals of Dermatology

Volumn 23, Issue 1, 2011, Pages 119-122

  Kim, Dong Ha ^a   Son, In Pyeong ^a   Lee, Jin Woong ^a   Lee, Hye In ^a   Kim, Beom Joon ^a   Kim, Myeung Nam ^a  

^a Chung Ang University   (South Korea)

Author keywords

Facial erythema; Hand foot skin reaction; Sorafenib

Indexed keywords

EID: 79955616797     PISSN: 10139087     EISSN: None     Source Type: Journal    
DOI: 10.5021/ad.2011.23.1.119     Document Type: Article

References (13)

1. Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 2006;12:7271-7278.
2. Llovet J, Ricci S, Mazzaferro V, Hilgard P, Raoul J, Zeuzem S, et al. Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCQ [abstract]. J Clin Oncol 2007;25:LBA1.
3. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-2512.
4. Strumberg D, Awada A, Hirte H, Clark JW, Seeber S, Piccart P, et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: is rash associated with treatment outcome? Eur J Cancer 2006;42:548-556.
5. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-7109.
6. Ito Y, Sasaki Y, Horimoto M, Wada S, Tanaka Y, Kasahara A, et al. Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology 1998;27:951-958.
7. Autier J, Escudier B, Wechsler J, Spatz A, Robert C. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol 2008;144:886-892. (Pubitemid 352039741)
8. Süsser WS, Whitaker-Worth DL, Grant-Kels JM. Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol 1999;40:367-398. (Pubitemid 29115299)
9. Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, Guitart J, et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008; 13:1001-1011.
10. Chu D, Lacouture ME, Fillos T, Wu S. Risk of hand-foot skin reaction with sorafenib: a systematic review and metaanalysis. Acta Oncol 2008;47:176-186.
11. Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 2009;161:1045-1051.
12. Park JH, Kim S, Choi SC, Lee ES, Yang JM. Cutaneous adverse effects associated with sorafenib therapy (Nexavar̄, BAY 43-9006). Korean J Dermatol 2008;46:141-143.
13. Kim HJ, Kim JH, Kim JB, Kim HK, Ko YS, Joh OJ, et al. A case of leukocytoclastic vasculitis after use of sorafenib (Nexavar̄ Korean J Dermatol 2008;46:648-651.